Compare HCC & TFX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HCC | TFX |
|---|---|---|
| Founded | 2015 | 1943 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Coal Mining | Medical/Dental Instruments |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.6B | 5.4B |
| IPO Year | 2017 | N/A |
| Metric | HCC | TFX |
|---|---|---|
| Price | $101.00 | $103.39 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 6 | 10 |
| Target Price | $76.40 | ★ $139.88 |
| AVG Volume (30 Days) | 750.1K | ★ 811.6K |
| Earning Date | 02-12-2026 | 02-26-2026 |
| Dividend Yield | 0.32% | ★ 1.32% |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.67 | N/A |
| Revenue | $1,224,320,000.00 | ★ $3,189,988,000.00 |
| Revenue This Year | N/A | $9.90 |
| Revenue Next Year | $47.01 | $10.51 |
| P/E Ratio | $149.58 | ★ N/A |
| Revenue Growth | N/A | ★ 5.42 |
| 52 Week Low | $38.00 | $102.58 |
| 52 Week High | $105.35 | $185.94 |
| Indicator | HCC | TFX |
|---|---|---|
| Relative Strength Index (RSI) | 79.63 | 30.69 |
| Support Level | $86.85 | $102.68 |
| Resistance Level | $105.35 | $106.53 |
| Average True Range (ATR) | 3.36 | 3.45 |
| MACD | 0.77 | -2.30 |
| Stochastic Oscillator | 77.05 | 2.86 |
Warrior Met Coal Inc is a U.S based company. It produces and exports of met coal that operates underground mines in Alabama. The company sells to steels manufacturers in Europe, Asia, and South America. Its mining operations consist of two underground met coal mines in Southern Appalachia's coal seam and other surface met and thermal coal mines. The Company generates ancillary revenues from the sale of natural gas extracted as a byproduct from the underground coal mines and royalty revenues from leased properties.
Teleflex is a Wayne, Pennsylvania-based manufacturer of hospital supplies and medical devices primarily in the bloodstream/vascular and surgical areas. The firm reports results across seven segments: vascular access (24% of 2024 sales), interventional (19%), anesthesia (13%), surgical (15%), interventional urology (11%), original-equipment manufacturing (11%), and other (7%). Geographic exposure for the business is primarily in the US, which accounts for 60% of revenue, with international markets making up the remainder.